175 related articles for article (PubMed ID: 27986268)
1. [Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients].
Stern N; Sakji I; Defachelles AS; Lervat C; Ryckewaert T; Marliot G; Peugniez C; Deplanque D; Penel N
Bull Cancer; 2017 Mar; 104(3):208-212. PubMed ID: 27986268
[TBL] [Abstract][Full Text] [Related]
2. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
[TBL] [Abstract][Full Text] [Related]
3. Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas.
Marina NM; Poquette CA; Cain AM; Jones D; Pratt CB; Meyer WH
J Pediatr Hematol Oncol; 2000; 22(2):112-8. PubMed ID: 10779023
[TBL] [Abstract][Full Text] [Related]
4. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
Szabatura AH; Cirrone F; Harris C; McDonnell AM; Feng Y; Voit D; Neuberg D; Butrynski J; Fisher DC
J Oncol Pharm Pract; 2015 Jun; 21(3):188-93. PubMed ID: 24664476
[TBL] [Abstract][Full Text] [Related]
5. Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.
Sweiss KI; Beri R; Shord SS
Drug Saf; 2008; 31(11):989-96. PubMed ID: 18840018
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors.
Tajino T; Kikuchi S; Yamada H; Takeda A; Konno S
J Orthop Sci; 2010 Jan; 15(1):104-11. PubMed ID: 20151259
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis.
Lo Y; Shen LJ; Chen WH; Dong YH; Wu FL
J Formos Med Assoc; 2016 Sep; 115(9):744-51. PubMed ID: 26302952
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide in the treatment of pediatric malignancies.
Voûte PA; van den Berg H; Behrendt H; Michiels E; de Kraker J
Semin Oncol; 1996 Jun; 23(3 Suppl 7):8-11. PubMed ID: 8711502
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide-induced encephalopathy due to a novel formulation of ifosfamide.
Filhon B; Lacarra B; Hervouet C; Jaffray M; Schneider P; Vannier JP
Pediatr Blood Cancer; 2016 Feb; 63(2):372-3. PubMed ID: 26397980
[No Abstract] [Full Text] [Related]
10. Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
Cormier JN; Patel SR; Herzog CE; Ballo MT; Burgess MA; Feig BW; Hunt KK; Raney RB; Zagars GK; Benjamin RS; Pisters PW
Cancer; 2001 Sep; 92(6):1550-5. PubMed ID: 11745234
[TBL] [Abstract][Full Text] [Related]
11. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
[TBL] [Abstract][Full Text] [Related]
12. Evaluating risk factors for the development of ifosfamide encephalopathy.
David KA; Picus J
Am J Clin Oncol; 2005 Jun; 28(3):277-80. PubMed ID: 15923801
[TBL] [Abstract][Full Text] [Related]
13. [Ifosfamide induced encephalopathy: 15 observations].
Dufour C; Grill J; Sabouraud P; Behar C; Munzer M; Motte J; Oberlin O; Paci A; Hartmann O
Arch Pediatr; 2006 Feb; 13(2):140-5. PubMed ID: 16364615
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide induced encephalopathy in a child with osteosarcoma.
Sarbay H; Demir ÜF; Yılmaz G; Atay AA; Malbora B
J Oncol Pharm Pract; 2021 Jul; 27(5):1302-1306. PubMed ID: 33023384
[TBL] [Abstract][Full Text] [Related]
15. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide in pediatric solid tumors.
Carli M; Passone E; Perilongo G; Bisogno G
Oncology; 2003; 65 Suppl 2():99-104. PubMed ID: 14586158
[TBL] [Abstract][Full Text] [Related]
17. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide-induced encephalopathy and movement disorder.
Ames B; Lewis LD; Chaffee S; Kim J; Morse R
Pediatr Blood Cancer; 2010 Apr; 54(4):624-6. PubMed ID: 19953647
[TBL] [Abstract][Full Text] [Related]
19. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
